ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2921

The Performance of the Newly Proposed EULAR/Acr Classification Criteria in Juvenile-Onset Systemic Lupus Erythematosus

Sezgin Sahin1, Sule Bektas1, Amra Adrovic1, Oya Koker2, Kenan Barut1 and Ozgur Kasapcopur3, 1Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, 2Istanbul University, Istanbul Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, 3Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: classification criteria, juvenile SLE and performance

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, October 24, 2018

Title: 6W008 ACR Abstract: Pediatric Rheum–Clinical III: Assessment Tools & Biomarkers (2916–2921)

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose:

To avoid misclassifications, a new set of classification criteria have been developed by the collaboration of the EULAR/ACR and the draft was presented at the 2017 ACR/ARHP Annual Meeting. To compare the sensitivity and specificity of the new EULAR/ACR criteria with those of the 1997 ACR criteria and 2012 SLICC criteria in juvenile-onset SLE patients.

Methods:

Juvenile SLE patients initially were evaluated by ACR-1997, SLICC-2012 and EULAR/ACR classification criteria at baseline. The diagnostic sensitivity of the three sets of classification criteria were further tested within 1 year of diagnosis and at last patient visit, longitudinally. Subjects with a clinical diagnosis other than SLE for at least 1 year-period, consecutively enrolled as controls.

Results:

A total of 104 juvenile-onset SLE patients were enrolled for the sensitivity performance of classification criteria at diagnosis and 104 controls (69 juvenile idiopathic arthritis, 9 juvenile systemic sclerosis, 5 juvenile dermatomyositis, 1 mixed connective tissue disease, 15 vasculitis and 5 other diseases) for specificity at their last visit. Since the follow-up period was less than 1 year, 12 SLE subjects excluded after baseline evaluation. Finally, 92 SLE subjects were eligible for sensitivity evaluation within 1 year of diagnosis and at last visit. The median age of the SLE patients at diagnosis of clinician was 13.0 years (range 3.1–17.9 years, interquartile range (IQR) 11.1–16.5 years) with median disease duration of 5.0 years (IQR 3.0-8.0 years). The female-to-male ratio was 4.7:1. The newly developed EULAR/ACR classification criteria were more sensitive than SLICC-2012 and ACR-1997 at diagnosis (93.3% versus 91.3% and 85.6%, respectively), and at first year (95.7% versus 94.6% and 90.2%, respectively (p>0.05). At last visit the sensitivity of the new set of criteria and SLICC-2012 were same (97.8 %), but higher compared to ACR-1997 criteria (95.7%). Specificity of the EULAR/ACR criteria (86.5%, n=90) were found to be higher than SLICC-2012 (81.7%, n=85). Compared to SLICC-2012, an additional 5 subjects among 104 controls without SLE succeeded to get rid of misclassification as SLE by the newly developed criteria. However, the performance of the new EULAR/ACR criteria in diagnostic specificity (86.5%), could not reach the level of ACR-1997 criteria (89.4%).

Conclusion:

Juvenile-onset systemic lupus erythematosus was classified by the newly proposed EULAR/ACR criteria with higher sensitivity compared with SLICC-2012 and ACR-1997 at disease onset and within one year of diagnosis. However, last visit assessment demonstrated equal sensitivity between new EULAR/ACR criteria and SLICC-2012. Although the difference was not significant, the new set of criteria seems to be capable of recruiting more children with juvenile SLE to clinical trials. The performance of the newly developed criteria seems more successful in specificity compared to the SLICC-2012. Application of the newly developed EULAR/ACR criteria to the juvenile-onset SLE patients resulted in higher sensitivity and specificity compared to SLICC-2012.


Disclosure: S. Sahin, None; S. Bektas, None; A. Adrovic, None; O. Koker, None; K. Barut, None; O. Kasapcopur, None.

To cite this abstract in AMA style:

Sahin S, Bektas S, Adrovic A, Koker O, Barut K, Kasapcopur O. The Performance of the Newly Proposed EULAR/Acr Classification Criteria in Juvenile-Onset Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-performance-of-the-newly-proposed-eular-acr-classification-criteria-in-juvenile-onset-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-performance-of-the-newly-proposed-eular-acr-classification-criteria-in-juvenile-onset-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology